Earnings Call · Q2 FY2022·2022-08-09

Q2 22EPS +3.95%·Rev n/aQ1 22EPS +67.16%·Rev n/aQ4 21EPS +47.67%·Rev n/aQ3 21EPS +19.18%·Rev n/a⚠ consensus missing

ADC Therapeutics SA ADCT

Amanda Hamilton — Investor Relations or Communications

Ameet Mallik — Chief Executive Officer

Jennifer Herron — Head of Commercial or similar commercial leadership role

Joe Camardo — Head of Clinical Development or similar clinical role

Jenn Creel — Chief Financial Officer

−1.0%1d on move date−0.6% vs SPY3d+0.9%5d+15.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ADCT calls or request research access.

More ADCT calls Browse calls Request research access